Skip to main content
. Author manuscript; available in PMC: 2014 Feb 24.
Published in final edited form as: Clin Med Insights Ther. 2013 Jan 15;2013(5):1–14. doi: 10.4137/CMT.S7824

Table 2.

A summary of the differences between ranolazine and the other traditional anti-anginal drugs in total costs of care and rate of revascularization in the pre- and post-index period.

Ranolazine (n = 881) Nitrates (n = 1788) β blockers/Ca2+ channel blockers (n = 1876)
pre-index total cost $ 19199 19841
(P = 0.603 vs. ranolazine)		 18152
(P = 0.410 vs. ranolazine)
% pre-index revascularization 24.97 26.51
(P = 0.394 vs. ranolazine)		 25.16
(P = 0.915 vs. ranolazine)
Unadjusted post-index total cost $ 14781 17773
(P = 0.022 vs. ranolazine)		 16785
(P = 0.120 vs. ranolazine)
% unadjusted post-index revascularization 9.88 20.25
(P < 0.001 vs. ranolazine)		 15.51
(P < 0.001 vs. ranolazine)
adjusted post-index total cost $ 13961 18166
(P < 0.001 vs. ranolazine)		 17612
(P = 0.002 vs. ranolazine)
% adjusted post-index revascularization 9.9 20.4
(P < 0.001 vs. ranolazine)		 15.4
(P < 0.001 vs. ranolazine)

Table assembled from Phelps et al. Clinical Therapeutics/volume 34, Number 6, 2012.